VYNE Therapeutics
VYNE
45 hedge funds and large institutions have $8.63M invested in VYNE Therapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 5 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
81% more capital invested
Capital invested by funds: $4.77M → $8.63M (+$3.86M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
18.64% more ownership
Funds ownership: 24.73% → 43.37% (+19%)
2% more funds holding
Funds holding: 44 → 45 (+1)
Top Buyers
Top Sellers
VYNE Hedge Fund Activity: Q1 2026 in Review
45 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2026, worth a combined $8.63M — up 81% from $4.77M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VYNE positions and 5 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $950K. The largest seller was Acadian Asset Management, cutting an estimated $150K.
- 45 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2026, up from 44 in Q4 2025.
- Funds reported $8.63M of VYNE Therapeutics stock for Q1 2026, up 81% quarter-over-quarter.
- 8 funds opened new VYNE Therapeutics positions in Q1 2026 and 5 closed out, a net change of +3 holders.
- The largest VYNE Therapeutics buyer in Q1 2026 was Lynx1 Capital Management, an estimated $950K added.
- The largest VYNE Therapeutics seller in Q1 2026 was Acadian Asset Management, an estimated $150K sold.
Based on aggregated 13F filings for Q1 2026.